Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK11 | Q15759 | 18/20 | 0.72 |
| ▸ | MAPK14 | Q16539 | 18/20 | 0.72 |
| ▸ | MAPK13 | O15264 | 6/20 | 0.56 |
| ▸ | MAPK12 | P53778 | 6/20 | 0.56 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.52 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1752365 | 0.92 | MAPK14 (0.71) | MAPK11MAPK14MAPK13MAPK12PRSS12 | |
| SCHEMBL1751622 | 0.86 | MAPK14 (0.76) | MAPK11MAPK14MAPK13MAPK12PRSS12 | |
| SCHEMBL1751247 | 0.85 | MAPK11 (0.77) | MAPK11MAPK14MAPK13MAPK12PRSS12 | |
| SCHEMBL1752282 | 0.84 | MAPK14 (0.72) | MAPK11MAPK14MAPK13MAPK12PRSS12 | |
| SCHEMBL12531327 | 0.84 | MAPK11 (1.00) | MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL12531326 | 0.83 | MAPK14 (0.71) | MAPK11MAPK14MAPK13MAPK12PRSS12 | |
| SCHEMBL1752547 | 0.83 | MAPK11 (0.71) | MAPK11MAPK14MAPK13MAPK12PRSS12 | |
| SCHEMBL1752167 | 0.82 | MAPK11 (0.92) | MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL1752127 | 0.79 | MAPK11 (0.79) | MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL1752491 | 0.77 | MAPK11 (0.90) | MAPK11MAPK14MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2468717-B1 | Heterocyclic Amide Compounds Useful as Kinase Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2013-11-20 | — | — | EP | disclosed |
| US-8404689-B2 | Heterocyclic amide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404689-B2 | Heterocyclic amide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-26 | — | — | US | disclosed |
| EP-2468717-A1 | Heterocyclic Amide Compounds Useful as Kinase Inhibitors | Bristol-Myers Squibb Company (US) | 2012-06-27 | — | — | EP | disclosed |
| US-20110160207-A1 | HETEROCYCLIC AMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-06-30 | — | — | US | disclosed |
| US-20110160207-A1 | HETEROCYCLIC AMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-06-30 | — | — | US | disclosed |
| US-7935696-B2 | e.g. 5-(4-Chlorophenyl)-N-(5-(cyclopropylcarbamoyl)-2-methylphenyl)furan-2-carboxamide; p38 alpha and beta kinase inhibitor; antiinflammatory agent; asthma, inflammatory bowel disease, osteoporosis, psoriasis, graft vs. host rejection, atherosclerosis, multiple myeloma, pain, myocardial ischemia | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935696-B2 | e.g. 5-(4-Chlorophenyl)-N-(5-(cyclopropylcarbamoyl)-2-methylphenyl)furan-2-carboxamide; p38 alpha and beta kinase inhibitor; antiinflammatory agent; asthma, inflammatory bowel disease, osteoporosis, psoriasis, graft vs. host rejection, atherosclerosis, multiple myeloma, pain, myocardial ischemia | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935696-B2 | e.g. 5-(4-Chlorophenyl)-N-(5-(cyclopropylcarbamoyl)-2-methylphenyl)furan-2-carboxamide; p38 alpha and beta kinase inhibitor; antiinflammatory agent; asthma, inflammatory bowel disease, osteoporosis, psoriasis, graft vs. host rejection, atherosclerosis, multiple myeloma, pain, myocardial ischemia | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-03 | — | — | US | disclosed |
| US-20080171741-A1 | HETEROCYCLIC AMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-07-17 | — | — | US | disclosed |
| US-20080171741-A1 | HETEROCYCLIC AMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-07-17 | — | — | US | disclosed |
| US-20080171741-A1 | HETEROCYCLIC AMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171741-A1 | HETEROCYCLIC AMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | MAP3K1, MAP3K8, MAP3K20 | MAPK11 47/4885MAPK14 43/4885MAPK13 46/4885 |
| US-20110160207-A1 | HETEROCYCLIC AMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | MAP3K1, MAP3K8, MAP3K20 | MAPK11 47/4885MAPK14 43/4885MAPK13 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.